drugset / Trial / NCT05590572
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
Phase 1/2
Not yet recruiting
148 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Chonnam National University · collabPeking University People's Hospital · collabQilu Hospital of Shandong University · collabRuijin Hospital · collabShanghai Jiao Tong University Affiliated Sixth People's Hospital · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a phase 1/2 study evaluating safety, tolerability, and efficacy of Sulfatinib in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed osteosarcoma ( combination Sulfatinib).
Timeline
- Start
- 2023-01
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etoposide | Small molecule | 60 mg/m2 | — |
| Subject | Etoposide | Small molecule | 80 mg/m2 | — |
| Subject | Etoposide | Small molecule | 100 mg/m2 | — |
| Subject | Ifosfamide | Small molecule | 1800 mg/m2 | — |
| Subject | Ifosfamide | Small molecule | 2400 mg/m2 | — |
| Subject | Ifosfamide | Small molecule | 3000 mg/m2 | — |
| Subject | Surufatinib | Small molecule | 300 mg | Oral |